{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000110","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.920271+00:00","generated_at":"2026-06-12T02:58:46.192983+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xeris Q2 revenue $38.0M record, up 50% YoY; tightens FY23 guidance upward","bullets":["Record total revenue $38.0M, QoQ +14%, YoY +50%; product revenue $36.9M (+46%).","Gvoke net revenue $15.6M (+36%), Keveyis $14.1M (+10%), Recorlev $7.2M.","FY23 revenue guidance tightened to $145M-165M from $135M-165M; cash utilization reduced to $57M-67M.","Cash, equivalents and short-term investments $80.7M at June 30; on track for cash flow breakeven by year-end.","Net loss $19.8M ($0.14 per share); Phase 2 study of XP-8121 (levothyroxine) began dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000110","json":"https://secwatch.observer/filing/0001867096-23-000110.json","markdown":"https://secwatch.observer/filing/0001867096-23-000110.md","text":"https://secwatch.observer/filing/0001867096-23-000110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000110/0001867096-23-000110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000110/xers-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:58:46.192983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b1c1c12d2cb309528271f78ca4c8fcdc8a7a17a8","claim":"Xeris Biopharma Holdings, Inc. reported full-year 2023 results: revenue $145 million to $165 million. Guidance raised.","evidence_excerpt":"performance, and expectations for the remainder of the year gives us the confidence to tighten our 2023 guidance by raising the low end of the total revenue range to $145 to $165 million from $135 to $165 million; reducing cash utilization range to $57 to $67 million from $57 to $77 million; improving year-end cash range to $55 to $65 million. And, we expect to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000110/0001867096-23-000110-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Revenue","value":"$145 million to $165 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"b3ee34ac086c51308e63a387d67811fdbad8ff3b","claim":"Xeris Biopharma Holdings, Inc. reported the three and six months ended June 30, 2023 results: revenue $38.0M, net income $19.8 million, or $0.14 per share, EPS $0.14 per share. Guidance raised.","evidence_excerpt":"expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- XERIS BIOPHARMA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Achieved record revenue of $38.0M – a 14% increase from prior quarter, and a 50% increase from same period prior year Ended Q2 with over $80M in cash, cash equivalents and short-term investments Tightens","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000110/0001867096-23-000110-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Revenue","value":"$38.0M"},{"label":"Net income","value":"$19.8 million, or $0.14 per share"},{"label":"EPS","value":"$0.14 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}